Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo-Controlled DISCOVER-1 Study.
Christopher T RitchlinAtul A DeodharWolf-Henning BoehnckeEnrique Roberto SorianoAlexa P KollmeierXie L XuFederico ZazzettiMay ShawiYusang JiangShihong ShengPhilip S HelliwellPublished in: ACR open rheumatology (2023)
Through 1 year, 100 mg of guselkumab Q4W and Q8W provided sustained improvements across multiple domains in both TNFi-naive and TNFi-experienced patients with active PsA.